.: ORİJİNAL ARAŞTIRMA
Assessment of Clinical Response to Aflibercept Treatment in Cases with Pigment Epithelial Detachment Associated with Neovascular Age-Related Macular Degeneration, Case Series
Neovasküler Yaşa Bağlı Makula Dejenerasyonu ile İlişkili Pigment Epitel Dekolmanı Olan Olgularda Aflibersept Tedavisine Klinik Yanıtın Değerlendirilmesi, Olgu Serileri
Turkiye Klinikleri J Ophthalmol. 2023;32(4):235-44
doi: 10.5336/ophthal.2023-98448
Makale Dili: EN
Tam Metin
Ücretsiz Erişim
ABSTRACT
Objective: To evaluate the clinical results of intravitreal aflibercept in patients with pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nvAMD). Material and Methods: The study included 50 patients who were newly diagnosed with nvAMD and had not received treatment. Patients with PED-related nvAMD received three loading doses of intravitreal aflibercept. The patients were followed up with a pro re nata protocol at 16, 24, and 32 weeks. Age, gender, best corrected visual acuity (BCVA), PED type, and PED localisation were recorded. PED width, PED height, central macular thickness (CMT), and the presence of intraretinal fluid, and subretinal fluid were recorded at the time of application and at subsequent follow-up examinations. Results: There were statistically significant decreases both in CMT and PED height compared to baseline in all follow-up measurements (p<0.001, p<0.001, respectively). There was a statistically significant increase in BCVA compared to baseline only at 32 weeks (p=0.044). The types of PED were compared according to height and width values and a statistically significant decrease was observed in hollow type PED values at 16 and 32 weeks compared to solid type (p=0.011, p=0.029) and mixed type PED values (p=0.031, p=0.038). Conclusion: Intravitreal aflibercept treatment is effective in decreasing the height and width of PED and CMT anatomically and increasing the BCVA functionally. Furthermore, there was seen to be less improvement in solid and mixed PED types than in the hollow type.
Keywords: Pigment epithelial detachment; aflibercept; neovascular age related macula degeneration
Objective: To evaluate the clinical results of intravitreal aflibercept in patients with pigment epithelial detachment (PED) associated with neovascular age-related macular degeneration (nvAMD). Material and Methods: The study included 50 patients who were newly diagnosed with nvAMD and had not received treatment. Patients with PED-related nvAMD received three loading doses of intravitreal aflibercept. The patients were followed up with a pro re nata protocol at 16, 24, and 32 weeks. Age, gender, best corrected visual acuity (BCVA), PED type, and PED localisation were recorded. PED width, PED height, central macular thickness (CMT), and the presence of intraretinal fluid, and subretinal fluid were recorded at the time of application and at subsequent follow-up examinations. Results: There were statistically significant decreases both in CMT and PED height compared to baseline in all follow-up measurements (p<0.001, p<0.001, respectively). There was a statistically significant increase in BCVA compared to baseline only at 32 weeks (p=0.044). The types of PED were compared according to height and width values and a statistically significant decrease was observed in hollow type PED values at 16 and 32 weeks compared to solid type (p=0.011, p=0.029) and mixed type PED values (p=0.031, p=0.038). Conclusion: Intravitreal aflibercept treatment is effective in decreasing the height and width of PED and CMT anatomically and increasing the BCVA functionally. Furthermore, there was seen to be less improvement in solid and mixed PED types than in the hollow type.
Keywords: Pigment epithelial detachment; aflibercept; neovascular age related macula degeneration
ÖZET
Amaç: Bu çalışmanın amacı, neovasküler yaşa bağlı makula dejenerasyonu [neovascular age-related macular degeneration (nvAMD)] ile ilişkili pigment epitel dekolmanı (PED) olan hastalarda intravitreal afliberseptin klinik sonuçlarını değerlendirmektir. Gereç ve Yöntemler: Çalışmaya yeni nvAMD tanısı almış ve tedavi almamış 50 hasta dâhil edildi. PED ile ilişkili nvAMD'si olan hastalara 3 yükleme dozu intravitreal aflibersept uygulandı. Hastalar 16, 24 ve 32. haftalarda pro re nata protokolü ile takip edildi. Yaş, cinsiyet, en iyi düzeltilmiş görme keskinliği [best corrected visual acuity (BCVA)], PED tipi ve PED lokalizasyonu kaydedildi. PED genişliği, PED yüksekliği, santral makula kalınlığı [central macular thickness (CMT)], intraretinal sıvı ve subretinal sıvı varlığı uygulama anında ve takip eden muayenelerde kaydedildi. Bulgular: Tüm takip ölçümlerinde başlangıca kıyasla hem CMT hem de PED yüksekliğinde istatistiksel olarak anlamlı düşüşler vardı (sırasıyla p<0,001, p<0,001). Sadece 32. Haftada başlangıca kıyasla BCVA'da istatistiksel olarak anlamlı bir artış oldu (p=0,044). PED tipleri boy ve genişlik değerlerine göre karşılaştırıldığında hollow tip PED değerlerinde 16 ve 32. haftalarda solid tip (p=0,011, p=0,029) ve mikst tip PED değerlerine (p=0,031, p=0,038) göre istatistiksel olarak anlamlı azalma gözlendi. Sonuç: İntravitreal aflibersept tedavisi anatomik olarak PED ve CMT'nin yükseklik ve genişliğini azaltmada ve fonksiyonel olarak BCVA'yı artırmada etkilidir. Ayrıca solid ve mikst PED tiplerinde hollow tipe göre daha az iyileşme olduğu görülmüştür.
Anahtar Kelimeler: Pigment epitel dekolmanı; aflibersept; neovasküler yaşa bağlı makula dejenarasyonu
Amaç: Bu çalışmanın amacı, neovasküler yaşa bağlı makula dejenerasyonu [neovascular age-related macular degeneration (nvAMD)] ile ilişkili pigment epitel dekolmanı (PED) olan hastalarda intravitreal afliberseptin klinik sonuçlarını değerlendirmektir. Gereç ve Yöntemler: Çalışmaya yeni nvAMD tanısı almış ve tedavi almamış 50 hasta dâhil edildi. PED ile ilişkili nvAMD'si olan hastalara 3 yükleme dozu intravitreal aflibersept uygulandı. Hastalar 16, 24 ve 32. haftalarda pro re nata protokolü ile takip edildi. Yaş, cinsiyet, en iyi düzeltilmiş görme keskinliği [best corrected visual acuity (BCVA)], PED tipi ve PED lokalizasyonu kaydedildi. PED genişliği, PED yüksekliği, santral makula kalınlığı [central macular thickness (CMT)], intraretinal sıvı ve subretinal sıvı varlığı uygulama anında ve takip eden muayenelerde kaydedildi. Bulgular: Tüm takip ölçümlerinde başlangıca kıyasla hem CMT hem de PED yüksekliğinde istatistiksel olarak anlamlı düşüşler vardı (sırasıyla p<0,001, p<0,001). Sadece 32. Haftada başlangıca kıyasla BCVA'da istatistiksel olarak anlamlı bir artış oldu (p=0,044). PED tipleri boy ve genişlik değerlerine göre karşılaştırıldığında hollow tip PED değerlerinde 16 ve 32. haftalarda solid tip (p=0,011, p=0,029) ve mikst tip PED değerlerine (p=0,031, p=0,038) göre istatistiksel olarak anlamlı azalma gözlendi. Sonuç: İntravitreal aflibersept tedavisi anatomik olarak PED ve CMT'nin yükseklik ve genişliğini azaltmada ve fonksiyonel olarak BCVA'yı artırmada etkilidir. Ayrıca solid ve mikst PED tiplerinde hollow tipe göre daha az iyileşme olduğu görülmüştür.
Anahtar Kelimeler: Pigment epitel dekolmanı; aflibersept; neovasküler yaşa bağlı makula dejenarasyonu
REFERANSLAR:
- Zayit-Soudry S, Moroz I, Loewenstein A. Retinal pigment epithelial detachment. Surv Ophthalmol. 2007;52(3):227-43. [Crossref] [PubMed]
- Yeo JH, Marcus S, Murphy RP. Retinal pigment epithelial tears. Patterns and prognosis. Ophthalmology. 1988;95(1):8-13. [Crossref] [PubMed]
- Axer-Siegel R, Ehrlich R, Rosenblatt I, Kramer M, Priel E, Yassur Y, et al. Photodynamic therapy for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Arch Ophthalmol. 2004;122(4):453-9. [Crossref] [PubMed]
- Nicolò M, Ghiglione D, Lai S, Calabria G. Intravitreal triamcinolone in the treatment of serous pigment epithelial detachment and occult choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005;15(3):415-9. [Crossref] [PubMed]
- Gross-Jendroska M, Flaxel CJ, Schwartz SD, Holz FG, Fitzke FW, Gabel VP, et al. Treatment of pigment epithelial detachments due to age-related macular degeneration with intra-ocular C3F8 injection. Aust N Z J Ophthalmol. 1998;26(4):311-7. [Crossref] [PubMed]
- Abdelfattah NS, Zhang H, Boyer DS, Sadda SR. Progression of macular atrophy in patients with neovascular age-related macular degeneration undergoing antivascular endothelial growth factor therapy. Retina. 2016;36(10):1843-50. [Crossref] [PubMed]
- Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina. 2013;33(8):1605-12. [Crossref] [PubMed]
- Patel KH, Chow CC, Rathod R, Mieler WF, Lim JI, Ulanski LJ 2nd, et al. Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye (Lond). 2013;27(5):663-7; quiz 668. [Crossref] [PubMed] [PMC]
- Au A, Parikh VS, Singh RP, Ehlers JP, Yuan A, Rachitskaya AV, et al. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Br J Ophthalmol. 2017;101(7):970-5. [Crossref] [PubMed]
- de Massougnes S, Dirani A, Ambresin A, Decugis D, Marchionno L, Mantel I. Pigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effects. Retina. 2016;36(5):881-8. [Crossref] [PubMed]
- Major JC Jr, Wykoff CC, Croft DE, Wang R, Mariani AF, Lehmann AE, et al. Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration. Can J Ophthalmol. 2015;50(5):373-7. [Crossref] [PubMed]
- Tyagi P, Juma Z, Hor YK, Scott NW, Ionean A, Santiago C. Clinical response of pigment epithelial detachment associated with neovascular age-related macular degeneration in switching treatment from Ranibizumab to Aflibercept. BMC Ophthalmol. 2018;18(1):148. [Crossref] [PubMed] [PMC]
- He L, Silva RA, Moshfeghi DM, Blumenkranz MS, Leng T. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina. 2016;36(3):492-8. [Crossref] [PubMed]
- Kocak I. Intravitreal aflibercept in treatment-resistant pigment epithelial detachment. Int Ophthalmol. 2017;37(3):531-7. [Crossref] [PubMed]
- Tran THC, Dumas S, Coscas F. Two-year outcome of aflibercept in patients with pigment epithelial detachment due to neovascular age-related macular degeneration (nAMD) refractory to ranibizumab. J Ophthalmol. 2017;2017:8984313. Erratum in: J Ophthalmol. 2018;2018:9171269. [Crossref] [PubMed] [PMC]
- Vaze A, Nguyen V, Daien V, Arnold JJ, Young SH, Cheung CM, et al; Fight Retinal Blindness Study Group. Ranibizumab and aflibercept for the treatment of pigment epithelial detachment in neovascular age-related macular degeneration: Data from an Observational Study. Retina. 2018;38(10):1954-61. [Crossref] [PubMed]
- Zinkernagel MS, Wolf S, Ebneter A. Fluctuations in pigment epithelial detachment and retinal fluid using a bimonthly treatment regimen with aflibercept for neovascular age-related macular degeneration. Ophthalmologica. 2016;235(1):42-8. [Crossref] [PubMed]
- Rouvas A, Chatziralli I, Androu A, Mpougatsou P, Alonistiotis D, Douvali M, et al. Ranibizumab versus aflibercept for the treatment of vascularized pigment epithelium detachment due to age-related macular degeneration. Int Ophthalmol. 2019;39(2):431-40. [Crossref] [PubMed]
- Kim K, Kim ES, Kim Y, Yang JH, Yu SY, Kwak HW. Outcome of intravitreal aflibercept for refractory pigment epithelial detachment with or without subretinal fluid and secondary to age-related macular degeneration. Retina. 2019;39(2):303-13. [Crossref] [PubMed]
- Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina. 2015;35(5):975-81. [Crossref] [PubMed]
- Dirani A, Ambresin A, Marchionno L, Decugis D, Mantel I. Factors influencing the treatment response of pigment epithelium detachment in age-related macular degeneration. Am J Ophthalmol. 2015;160(4):732-8.e2. [Crossref] [PubMed]
- Balaskas K, Karampelas M, Horani M, Hotu O, Keane P, Aslam T. Quantitative analysis of pigment epithelial detachment response to different anti-vascular endothelial growth factor agents in wet age-related macular degeneration. Retina. 2017;37(7):1297-304. [Crossref] [PubMed]
- Doguizi S, Ozdek S. Pigment epithelial tears associated with anti-VEGF therapy: incidence, long-term visual outcome, and relationship with pigment epithelial detachment in age-related macular degeneration. Retina. 2014;34(6):1156-62. [Crossref] [PubMed]
- Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GF, Schlingemann RO. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest Ophthalmol Vis Sci. 2002;43(3):849-57. [PubMed]
- Blaauwgeers HG, Holtkamp GM, Rutten H, Witmer AN, Koolwijk P, Partanen TA, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris. Evidence for a trophic paracrine relation. Am J Pathol. 1999;155(2):421-8. [Crossref] [PubMed] [PMC]
- Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98(6):813-25. [Crossref] [PubMed]
- Pauleikhoff D, Löffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A, et al. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240(7):533-8. [Crossref] [PubMed]
.: İşlem Listesi